Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inulin with Fruquintinib and Sintilimab in Metastatic Colorectal Cancer
NCT06347198Phase 1Recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of inulin in metastatic colorectal cancer (mCRC) (2 arms). Primary endpoints: Intestinal microbiota diversity, abundance and taxonomic information at 6 months and Adverse events. Started Apr 2024; status: recruiting.
02
Drugs
inulin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06347198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06347198.